Background: Serum β-cryptoxanthin levels are lower in overweight subjects than in normal subjects. Abnormalities of adipocytokine profiles in obesity subjects have been reported. There are several reports that serum β-cryptoxanthin levels in them were relatively lower than normal subjects.
Introduction
Serum β-cryptoxanthin levels (Figure 1 ) are lower in overweight subjects than in normal subjects, irrespective of dietary intake [1] . In a case-controlled study, which was part of a larger survey of 2895 subjects with body mass indexes (BMI) greater than 25, serum β-cryptoxanthin levels were found to be lower than in subjects with BMIs lower than 25 [2] . Adipose tissue store excess energy in the form of fat and secretes physiologically active substances known as adipocytokines [3] . Among these compounds, adiponectin is the most abundant adipose-specific protein.
Plasma adiponectin levels are negatively correlated with BMI in men and women [4] . Growing evidence suggests that high-molecular weight (HMW)-adiponectin is the most physiologically active form present in metabolic disorders [5] . Plasminogen activator inhibitor-1 (PAI-1) is a non-specific adipocytokine and its levels are positively correlated with the area of visceral fat determined by computed tomography (CT) scan of obese and non-obese subjects [6] .
Serum β-cryptoxanthin levels have been reported in subjects with metabolic syndrome [1] , but no intervention studies have provided dietary β-cryptoxanthin to subjects. We hypothesize that supplementation of highly concentrated β-cryptoxanthin improves serum adipocytokine profiles in obese subjects. This study aimed to assess the degree of adiposity and serum adipocytokine levels in middle-aged postmenopausal women with a BMI of 25-30, who had been administered a beverage containing high concentrations of β-cryptoxanthin for 3 weeks.
Methods and materials

Subjects
Seventeen postmenopausal obese women participated in this study. Obesity was defined as a body mass index (BMI) greater than 25 kg/m 2 , according to the Japan Society for the Study of Obesity. Criteria for participation in this study included no past history of diabetes mellitus, no use of prescribed medicine, and no history of smoking. This study was approved by the Nakamura Gakuen University Committee (No. 05-009), in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
The daily nutrient intake of the subjects was monitored for 3 days before the start and 3 days after the study by means of dietary records. Subjects were instructed to continue with their usual diets, but were prohibited from the intake of citrus fruits, persimmon, and the juices of either fruits during the period of the investigation. The nutrient intake was calculated using Excel Eiyou-kun ver. 3 (Kenpaku-sha, Tokyo, Japan). The intervention study was a 3-week long before-andafter controlled trial, where 200 ml of a beverage containing β-cryptoxanthin (1.56 mg/serving and 4.7 mg/ day) was provided to the subjects. Other ingredients of the beverage which we determined were as follows, energy (27 kcal/serving), water (183.4 g/serving), protein (0.6 g/serving), lipids (< 0.2 g/serving), ash (< 0.2 g/ serving), total carbohydrate (6.1 g/serving), sugars (3.78 g/serving), dietary fiber (1.1 g/serving), potassium (71.6 mg/serving), calcium (12.0 mg/serving), sodium (0.8 mg/serving), magnesium (5.7 mg/serving), vitamin C (49.10 mg/serving), β-carotene (0.19 mg/serving). The beverage was prepared from residues generated by the process used in the manufacture of satsuma mandarin juice. The residues contained higher concentrations of β-cryptoxanthin than the manufactured juice. The beverage was prepared by resuspending the residues in water, and β-cryptoxanthin levels in the beverage were identical in each serving.
Blood sampling and biochemical measurements
Blood samples were assayed for total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, glucose, HMW-adiponectin, leptin, total PAI-1, and insulin in a commercial laboratory (SRL, Fukuoka, Japan). Plasma carotenoid levels were measured in a commercial laboratory (BIKEN, Kyoto, Japan). Plasma carotenoids, including, α -carotene, β-carotene, β-cryptoxanthin, lycopene, and lutein-zeaxanthin, were extracted and concentrated using standard methods. These compounds were then quantified by reversed-phase highperformance liquid chromatography (HPLC).
Statistical analyses
All values are expressed as mean ± SE. The statistical difference was determined using a two-tailed paired t-test. P < 0.05 was considered significant.
Results
The baseline characteristics of the subjects at the beginning of the investigation are shown in Table 1 . Postmenopausal women were selected on the basis of BMI. The highest BMI was 32.1 and the lowest was 23.1. There were no differences in body weight or BMI after the treatment. Serum triglyceride levels at the end of the study tended to decrease (P = 0.057). There were no significant differences in total serum low-density Figure 1 The chemical structure of β-cryptoxanthin. lipoprotein (LDL) and HDL cholesterol levels. Subjects had blood pressure measurements in the normal range at the beginning of the study, and this was also the case for the serum parameters (Table 2) . After drinking the beverage containing β-cryptoxanthin for 3 weeks, serum β-cryptoxanthin levels significantly increased 4-fold. The results show that serum HMWadiponectin levels at the end of the study were significantly higher compared with the initial period. Serum total PAI-1 levels at the end of the study tended to be lower (P = 0.052). The levels of other carotenoids, such as lycopene, α-carotene, β-carotene, and zeaxanthin, were not significantly different after the treatment.
Discussion
This study investigated the potential effects of β-cryptoxanthin supplementation on obesity. There were no significant effects on body weight and BMI after the 3-week treatment. However, β-cryptoxanthin supplementation improved the adipocytokine status, as indicated by increased serum HMW-adiponectin levels and decreased PAI-1 levels. A previous study [7] reported that a Mediterranean diet leads to increased serum adiponectin levels in metabolic syndrome subjects. In a short-term study, Shimada et al. [8] reported that supplementation of the diet of 17 elderly men with normal BMI values with Oolong tea (1,000 ml/day) for 4 weeks increased the plasma adiponectin levels, but without any decrease in body weight. Sluijs et al. [9] reported that higher intake of dietary carotenoid, particularly β-cryptoxanthin and lycopene, was associated with a reduced prevalence of metabolic syndrome in middle-aged elderly men. Daily βcryptoxanthin intakes in the Sluijs et al. [9] study were 1/37 th of that found in the current study. However, the dietary β-carotene and lycopene intake in the Sluijs et al. [9] study was almost the same as that found in the current study. Thus, daily consumption of milligramscale carotenoids, including, β-carotene, lycopene, and β-cryptoxanthin, might alleviate metabolic syndrome.
Jones et al. [10] reported a correlation between serum PAI-1 levels and carotenoid bioavailability in an intervention study, where fish-oil esters of plant sterols were added to the diets of moderately overweight and hypercholesterolemic subjects over a period of 4 weeks. Compared with supplementation with safflower oil esters, supplementation with fish-oil esters of plant sterols significantly elevated the serum levels of retinol and β-carotenes and decreased serum PAI-1 levels. Thus, an increased in serum carotenoid levels might result in a decrease of serum PAI-1 levels. In this study, serum βcryptoxanthin levels increased, whereas PAI-1 levels decreased.
In conclusion, increasing β-cryptoxanthin intake to approximately 4 mg per day for 3 weeks could have beneficial effects on serum adipocytokine status, and subsequently alleviate progression of metabolic syndrome. Further case-control study in larger scale may be needed to prove sound relationships between βcryptoxanthin intake and the risk of development of metabolic syndrome. Data show means ± S. E. Abbreviations: FBG, fasting blood glucose; HMW, high molecular weight; PAI-1, plasminogen activator inhibitor-1* Change implies subtraction of 'before' data from 'after' data.
